A 30-year-old woman with β-thalassemia, a recessively inherited genetic disorder caused by absence of the hemoglobin β chain, had been treated with blood transfusions since the age of 7. However, in spite of the transfusions, her health was declining. As an alternative treatment, her physician administered 5-azacytidine to induce transcription of the fetal β hemoglobin chain to replace her missing β chain. This drug activates gene transcription by removing methyl groups from DNA. Addition of methyl groups silences genes. However, the physician expressed concern that approximately 40 percent of all human genes are normally silenced by methylation. Nevertheless, after several weeks of 5-azacytidine treatment, the patient’s condition improved dramatically. Although the treatment was successful, use of this drug raises several important questions.
What criteria would you use when deciding to administer a drug such as 5-azacytidine?
We need at least 10 more requests to produce the solution.
0 / 10 have requested this problem solution
The more requests, the faster the answer.